Cognitive functioning in a cohort of high-grade glioma patients
, , , , , et
21 juin 2023
À propos de cet article
Catégorie d'article: Research Article
Publié en ligne: 21 juin 2023
Pages: 201 - 210
Reçu: 29 nov. 2022
Accepté: 31 déc. 2022
DOI: https://doi.org/10.2478/raon-2023-0009
Mots clés
© 2023 Andreja Cirila Skufca Smrdel et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.

Number of patients with different combinations of IDH1 mutation expression and methyl guanine methyl transferase (MGMT) methylation
5 | 10 | 15 | |
49 | 26 | 75 | |
54 | 36 | 90 |
Cognitive functioning regarding to isocitrate dehydrogenase 1 (IDH1) mutation
TMT A | 53 | 3.12 |
15 | 2.06 (2.23) | 72 | 46 | ||
TMT B | 33 | 2.82 |
13 | 2.76 (2.57) | 82 | 60 | ||
SCOWA | 66 | −1.28 (0.87) | 15 | −0.86 (0.84) | 51 | 27 | ||
SVLT-ir | 65 | −1.98 (1.06) | 15 | −1.15 (1.12) | 71 | 33 | ||
SVLT-sr | 65 | −2.20 (1.29) | 15 | −1.37 (1.22) | 84 | 53 | ||
SVLT-dr | 65 | −2.14 (1.27) | 15 | −0.98 (1.34) | 69 | 33 | ||
SVLT-recog | 65 | −3.06 |
15 | −1.24 (1.91) | 29 | 26 |
Demographic and medical data
Gender | Male | 57 (63%) | |
Female | 33 (37%) | ||
Age | < 50 years | 17 (19%) | M = 58.78, SD = 11.31 |
50–70years | 60 (67%) | ||
> 70 years | 13 (14%) | ||
Education | ≤9 years | 14 (16%) | |
10–13 years | 48 (53%) | ||
14–19 years | 26 (29%) | ||
≥20 years | 2 (2%) | ||
Tumour grade | Grade III | 12 (13%) | |
Grade IV | 78 (87%) | ||
Tumour location | Frontal | 34 (38%) | |
Parietal | 21 (23%) | ||
Temporal | 26 (29%) | ||
Occipital | 4 (4%) | ||
central | 3 (3%) | ||
Diffuse | 2 (2%) | ||
Hemisphere | Right | 38 (42%) | |
Left | 44 (49%) | ||
Both | 8 (9%) | ||
Surgery type | Biopsy | 11 (12%) | |
Reduction | 49 (54%) | ||
Gross tumour resection | 30 (33%) | ||
Karnoffsky performance status | 70 | 32 (36%) | |
80 | 37 (41%) | ||
90 | 18 (20%) | ||
100 | 3 (3%) | ||
Corticosteroids (Yes/no, mg) | Yes | 66 (73%) | M = 5.55, SD = 4.73 |
No | 24 (27%) | ||
Radio-chemotherapy (intention to treat) | Yes | 90 (100%) | |
No | 0 (0%) | ||
Time to beginning of adjuvant treatment (in weeks) | ≤ 6 weeks | 60 (67%) | M = 5.98, SD = 2.25 |
≥ 7 weeks | 30 (33%) | ||
Epilepsy | Yes | 27 (30%) | |
No | 63 (70%) | ||
IDH1 mutation | IDH1 mutation | 15 (17%) | |
IDH1 wild type | 75 (83%) | ||
MGMT methylation* | Yes | 36 (42%) | |
No | 50 (58%) |
Patient characteristics, regarding isocitrate dehydrogenase 1 (IDH1) mutation
Age mean (min/max/SD) | 61.50 (31 / 84 / 9.21) | 38.75 (30 / 67 / 3.86) | |
Sex (female / male) | 29 / 46 | 4 / 11 | |
Education level (≤ 9 years /10–13 years / 14–19 years / ≥ 20 years) | 11 / 40 / 22 / 2 | 3 / 8 / 4 / 0 | |
KPS (70/80/90/100) | 31 / 34 / 7 / 3 | 1 / 3 / 11 / 0 | |
WHO grade (III / IV) | 1 /74 | 11 /4 | |
Corticosteroids mg (min/max/SD) | 2 (0 / 16 / 6) | 5 (0 / 24 / 4.5) | |
biopsy/reduction/gross tumour resection | 9 / 44 / 22 | 2 / 5 / 8 | |
Tumour location (frontal / temporal / parietal / occipital / diffuse / central) | 26 / 20 / 21 / 4 / 2 / 2 | 8 / 1 / 5 / 0 / 1 / 0 | NA |
Hemisphere (right / left / both) | 21 / 27 / 6 | 17 / 17 / 2 | |
MGMT (yes / no) | 10 / 5 | 26 /49 |
Cognitive functioning regarding methyl guanine methyl transferase (MGMT) methylation
TMT A | 26 | 2.67 (3.01) | 42 | 3.03 |
69 | 66 | ||
TMT B | 20 | 3.22 (2.30) | 26 | 2.48 |
86 | 74 | ||
SCOWA | 33 | −1.25 (0.87) | 48 | −1.18 |
50 | 44 | ||
SVLT-ir | 32 | −1.85 (1.27) | 48 | −1.82 |
64 | 67 | ||
SVLT-sr | 32 | −2.03 (1.32) | 48 | −2.06 (1.32) | 75 | 81 | ||
SVLT-dr | 32 | −1.98 (1.52) | 48 | −1.89 (1.25) | 66 | 61 | ||
SVLT-recog | 32 | −2.731 (4.24) | 48 | −2.72 |
58 | 61 |
Patient characteristics regarding methyl guanine methyl transferase (MGMT) methylation
Age mean (min/max/SD) | 58.94 (31 / 84 / 10.42) 1 | 58,53 (30 / 78 / 12.67) | |
Sex (female / male) | 19 / 35 | 14 / 22 | |
Education level (≤9 years /10–13 years / 14–19 years / ≥ 20 years) | 8 / 19 / 11 / 0 | 9 / 29 / 15 / 2 | |
KPS (70/80/90/100) | 20 / 23 / 9 / 2 | 12 / 14 / 9 /1 | |
WHO grade (III / IV) | 3 / 51 | 9 / 27 | |
Corticosteroids mg (min/max/SD) | 5.67 (0 /24 / 5,04) | 5.48 (0 / 16 / 4.22) | |
Biopsy/reduction/gross tumour resection | 9 / 31 / 14 | 2 / 18 / 16 | |
Tumour location (frontal / temporal / parietal / occipital / diffuse / central) | 26 / 20 / 21 / 4 / 2 / 2 | 8 / 1 / 5 / 0 / 1 / 0 | NA |
Hemisphere (right / left / both) | 28 / 40 / 7 | 10 / 4 / 1 | |
IDH1 (yes / no) | 5 / 49 | 10 / 26 |
Descriptive statistics for standardized test scores (z–values) and proportion of impaired patients in psychological cognitive functioning tests
Visual – motor speed | TMT A | 68 | 68 | 57 | 2.89 | 3.57 |
Executive function | TMT B | 78 | 46 | 59 | 2.80 | 2.94 |
Verbal fluency | SCOWA | 47 | 81 | 41 | −1.21 | 0.88 |
Memory | ||||||
immediate recall | SVLT-ir | 64 | 80 | 60 | −1.83 | 1.11 |
short delayed recall | SVLT-sr | 79 | 76 | −2.05 | 1.31 | |
delayed recall | SVLT-dr | 63 | 58 | −1.92 | 1.35 | |
recognition | SVLT-recog | 60 | 52 | −2.73 | 3.36 |